Mitomycin C
Mitomycin C (MitomycinC, MMC) is antineoplastic classified in an anticancerous antibiotic (anticancer agent). I belong to group 2 of the list of IARC carcinogenicity risks by the substructure of the World Health Organization (WHO). There are carcinogenic limited evidence for the Homo sapiens, enough evidence by the animal experiment.
 | |
| Material name by the IUPAC glossology | |
|---|---|
| (1aS,8S,8aR,8bR) -6-Amino-4,7- dioxo-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5- methylazirino[2,3:3,4]pyrrolo[1,2-α]indol-8-ylmethylcarbamate | |
| Clinical data | |
| Fetus degree of risk classification | |
| Legal regulation | |
| Dosage method | Intravenous injection, intravesical infusion |
| Pharmacokinetics data | |
| Bioavailability | - |
| Plasma protein combination | 8.4-12.8% |
| Metabolism | It is liver mainly |
| Half-life | α aspect: 1.3-5.2 minutes A beta phase: 32.9-50.2 minutes |
| Identification | |
| CAS number (MeSH) | 50-07-7 |
| ATC cord | L01DC03 (WHO) |
| PubChem | CID: 5746 |
| DrugBank | APRD00284 |
| KEGG | D00208 |
| Chemical data | |
| Chemical formula | C15H18N4O5 |
| Molecular weight | 334.327 |
Mitomycin is one anticancerous antibiotic obtained from the culture filtrate of Streptomyces caespitosus discovered in 1955 by Toju Hata and others of Kitasato Inst. [1]. Stability was high, and mitomycin C having the strongest anti-tumor activity was isolated as a purple crystal from that by Shigetoshi Wakaki and others of Kyowa Hakko Kogyo [2].
The brand name mitomycin (sale: Kyowa Hakko Kirin Co., Ltd.).
Yoshito Kishi of Harvard University succeeded in composition [3].
Table of contents
Effect, effect
Chronic lymphocytic leukemia, chronic myelogenous leukemia, stomach cancer, colon, rectal cancer, lung cancer, pancreatic cancer, liver cancer, cervical cancer, endometrial cancer, breast cancer, head and neck tumor, bladder tumor
Side effect
The serious side effect is the uremic syndrome that is hemolytic, a microvessel symptom-related hemolytic anemia, renal damage (acute renal failure), myeloablation (pancytopenia, leukopenia (40.2%), neutropenia, thrombopenia (24.7%), bleeding tendency (3.6%), anemia (3.0%)), stroma-related pneumonia, pulmonary fibrosis, shock, an anaphylactoid symptom, a liver, biliary tract disorder (cholecystitis, bile duct necrosis, liver parenchyma disorder).
The side effect that frequency (documents investigation at the time of the reevaluation) is listed in in other attached documents is inappetence (21.8%), nausea, vomiting (15.4%), lassitude (5.6%), a weight loss (5.5%). Cystitis, hematuria occur at the time of the bladder infusion than 5%.
Action mechanism
Mitomycin C is returned by various enzymes and becomes the plural active metabolite and inhibits a reproduction of DNA through the bridging formation, alkylation to DNA, the DNA chain cutting with the free radical, and it is thought that I show an antitumor effect [4]: 10-13. The active metabolite is thought to be the Mito sen () derivative which is an N-alkylating agent.
Use except cancer
When an ophthalmology operation () sometimes uses mitomycin C 0.02%, I see fog after glaucoma filtration postoperative scarring and ラセック or LASIK and can prevent を. In addition, scarring by the squint operation () is reduced, too [5].
I prevent restenosis when I apply mitomycin C to a mucous membrane after art of expansion of respiratory tract stenosis and the stricture of the esophagus promptly and can reduce generation of a fibroblast and the scar tissue.
Source
- ^ HATA T, HOSHI T, KANAMORI K, MATSUMAE A, SANO Y, SHIMA T et al. (1956). "Mitomycin, a new antibiotic from Streptomyces. I.". J Antibiot (Tokyo) 9 (4): 141-6. It is . PMID 13385186
- ^ WAKAKI S, MARUMO H, TOMIOKA K, SHIMIZU G, KATO E, KAMADA H et al. (1958). "Isolation of new fractions of antitumor mitomycins.". Antibiot Chemother (Northfield) 8 (5): 228-40. It is . PMID 24544727
- ^ "The Total Synthesis of Mitomycins". J. Nat. Prod. 42 (6): 549-68. (1979-11). doi: 10.1021/np50006a001 June 18, 2016 reading. .
- ^ "2 mg for the mitomycin note, 10 mg of interview forms (PDF)". Kyowa Hakko Kirin Co., Ltd. (June, 2014). June 18, 2016 reading.
- ^ Kersey JP, Vivian AJ (Jul–Sep 2008). "Mitomycin and amniotic membrane: a new method of reducing adhesions and fibrosis in strabismus surgery." Strabismus 16 (3): 116–118. doi: 10.1080/09273970802405493. PMID 18788060.
Allied item
This article is taken from the Japanese Wikipedia Mitomycin C
This article is distributed by cc-by-sa or GFDL license in accordance with the provisions of Wikipedia.
In addition, Tranpedia is simply not responsible for any show is only by translating the writings of foreign licenses that are compatible with CC-BY-SA license information.
0 개의 댓글:
댓글 쓰기